Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and …
CG Gialouri, S Moustafa, K Thomas… - Rheumatology …, 2023 - Springer
JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-
mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid …
mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid …
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis
(UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited …
(UC). Real-world data comparing the effectiveness of tofacitinib to ustekinumab are limited …
托法替尼治疗溃疡性结肠炎的研究进展
吴澎泞， 熊帅， 杨婉卿， 陈敏 - 中国药房, 2023 - journal.china-pharmacy.com
溃疡性结肠炎(UC) 是一种多因素导致的慢性炎症性肠病, 其病因和发病机制尚不完全清楚.
托法替尼是一种小分子物质, 主要通过抑制Janus 激酶(JAK) 治疗UC, 可通过口服快速吸收 …
托法替尼是一种小分子物质, 主要通过抑制Janus 激酶(JAK) 治疗UC, 可通过口服快速吸收 …